| scholarly article | Q13442814 |
| P50 | author | C-C Tseng | Q84794546 |
| P2093 | author name string | Yu-Tzu Chang | |
| An-Bang Wu | |||
| Ming-Cheng Wang | |||
| Wei-Hung Lin | |||
| Te-Hui Kuo | |||
| Hung-Hsiang Liou | |||
| Jo-Yen Chao | |||
| P2860 | cites work | Wnt/beta-catenin signaling in development and disease | Q27860784 |
| Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) | Q28236767 | ||
| Romosozumab Treatment in Postmenopausal Women with Osteoporosis | Q28278665 | ||
| WNT signaling in bone homeostasis and disease: from human mutations to treatments | Q28285090 | ||
| Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women | Q33786865 | ||
| Regulation of bone mass by Wnt signaling | Q34576629 | ||
| Sclerostin and Dickkopf-1 in renal osteodystrophy | Q34751932 | ||
| Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. | Q35230055 | ||
| Osteoporosis in chronic kidney disease. | Q35674619 | ||
| A review of two journals found that articles using multivariable logistic regression frequently did not report commonly recommended assumptions. | Q35965374 | ||
| Serum sclerostin increases in healthy adult men during bed rest. | Q36201481 | ||
| The relation between renal function and serum sclerostin in adult patients with CKD. | Q36810475 | ||
| Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women | Q36820702 | ||
| Serum Sclerostin as an Independent Marker of Peripheral Arterial Stiffness in Renal Transplantation Recipients: A Cross-Sectional Study | Q36822357 | ||
| The Wnt signaling pathway and bone metabolism | Q36841385 | ||
| A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair | Q36973896 | ||
| Biochemical markers of bone turnover - uses and limitations | Q38176560 | ||
| Low bone mineral density and fractures in stages 3-5 CKD: an updated systematic review and meta-analysis | Q38283483 | ||
| Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters | Q39395889 | ||
| The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women | Q39413639 | ||
| The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations | Q39975961 | ||
| Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness | Q40031994 | ||
| Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals | Q41108649 | ||
| Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? | Q44010748 | ||
| Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. | Q44171393 | ||
| Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study | Q44263716 | ||
| The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure | Q44911358 | ||
| Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. | Q45268599 | ||
| Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients | Q46279027 | ||
| Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease | Q46953148 | ||
| Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. | Q47209031 | ||
| Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients | Q47621636 | ||
| Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know | Q47630210 | ||
| Bone mineral density: serum markers of bone turnover and their relationships in peritoneal dialysis | Q47669025 | ||
| Usefulness of bone resorption markers in hemodialysis patients. | Q51647198 | ||
| Serum sclerostin level might be a potential biomarker for arterial stiffness in prevalent hemodialysis patients. | Q51679309 | ||
| Decreased Plasma Levels of Sclerostin But Not Dickkopf-1 are Associated with an Increased Prevalence of Osteoporotic Fracture and Lower Bone Mineral Density in Postmenopausal Korean Women. | Q51707392 | ||
| Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. | Q51789429 | ||
| FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. | Q53189719 | ||
| Comparison of vascular calcification scoring systems using plain radiographs to predict vascular stiffness in peritoneal dialysis patients. | Q53424893 | ||
| Circulating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus | Q58868186 | ||
| The effect of overlying calcification on lumbar bone densitometry | Q68045419 | ||
| Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone | Q73235636 | ||
| A study on the influence of calcified intervertebral disk and aorta in determining bone mineral density | Q74445110 | ||
| Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure | Q78197798 | ||
| Correlation between bone mineral density and intervertebral disk degeneration in pre- and postmenopausal women | Q78686995 | ||
| Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients | Q80447035 | ||
| Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients | Q81219407 | ||
| Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide | Q83390478 | ||
| Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients | Q84196782 | ||
| Determinants of serum sclerostin in healthy pre- and postmenopausal women | Q84661349 | ||
| Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls | Q84981661 | ||
| Chronic kidney disease and bone metabolism | Q86663695 | ||
| Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? | Q87182883 | ||
| Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis | Q87309123 | ||
| Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients | Q87436498 | ||
| Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients | Q87506808 | ||
| P433 | issue | 1 | |
| P921 | main subject | peritoneal dialysis | Q1756474 |
| P304 | page(s) | 266 | |
| P577 | publication date | 2019-07-17 | |
| P1433 | published in | BMC Nephrology | Q15750891 |
| P1476 | title | Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study | |
| P478 | volume | 20 |
Search more.